Key Takeaways
- Low copper can weaken glucose control and strain insulin producing cells.
- Ceruloplasmin helps carry copper and move iron out of tissues.
- Rare ceruloplasmin deficiency can show up as diabetes before brain symptoms.
- Blood tests can confuse the picture when inflammation or kidney loss is present.
- Unusual diabetes cases may need copper, iron and genetic testing.
Copper & Blood Sugar
Copper In Cells
Copper helps several enzymes do basic work inside the body. Those enzymes help cells make energy, manage oxidative stress and handle iron in a safe way. Low copper can strain tissues that need steady energy every day, especially the liver, muscles and pancreas (1, 2).
Insulin sensitivity depends on healthy cell energy use. Poor copper handling can interfere with that process and make blood sugar control less steady over time. Research on ordinary diabetes does not show one clean blood copper pattern, though it does show that copper balance often goes off track in metabolic disease (3, 4).
Ceruloplasmin Work
Ceruloplasmin is a protein made mostly in the liver. It carries most of the copper found in blood and helps iron leave cells in a form the body can use. Low ceruloplasmin can leave copper transport weak while iron starts collecting in tissues where it can cause harm (5, 6).
The pancreas is one of the organs that can suffer when iron builds up in the wrong place. Oxidative stress can rise, insulin producing cells can get damaged and blood sugar can start to drift. A low ceruloplasmin state can therefore affect glucose control through copper loss and iron overload at the same time (2, 5).
Deficiency & Diabetes
Rare Genetic Disease
Aceruloplasminemia is a rare inherited disease where ceruloplasmin is absent or very low. People with this condition can develop anemia, eye problems, nerve or brain symptoms and diabetes. Diabetes can appear years before the later neurologic signs become clear, which makes early diagnosis easy to miss (7, 8, 9).
Several case reports describe adults with diabetes who did not fit the usual type 2 picture. Some were lean. Some had odd iron results. Some were only diagnosed after a deeper workup found very low ceruloplasmin and iron overload in several organs (7, 10, 11).
Pancreas Injury
Pathology studies found iron deposition and structural changes in the pancreatic islets of people with hereditary ceruloplasmin deficiency. The islets are the small cell clusters that make insulin. Tissue injury in that area gives a direct reason for worsening glucose control in this disease (12, 8).
Low ceruloplasmin is not just a low copper number on a lab sheet. Poor copper transport, rising oxidative stress and iron trapped in tissue can all show up together. Insulin output can fall while other tissues also respond less well to insulin already in circulation (2, 5).
Mixed Evidence
Evidence is much stronger for rare ceruloplasmin deficiency than for ordinary type 2 diabetes. Case reports, pathology findings and review papers support a clear path from very low ceruloplasmin to pancreatic iron loading and diabetes. Blood studies in broader diabetes groups are less tidy and often point in different directions (5, 7, 12).
Some studies found higher blood copper or higher ceruloplasmin in diabetes rather than lower values. Inflammation can raise ceruloplasmin. Kidney disease can change copper related markers too. One blood result on its own can easily tell the wrong story (3, 4, 13).
Testing & Context
Reading The Labs
Ceruloplasmin is an acute phase protein. Infection, inflammation or other stress can push it upward even when copper handling is poor. A person can therefore have a normal looking or high ceruloplasmin level without having normal copper biology (2, 13).
Kidney disease adds another layer of confusion. Diabetes can increase urinary loss of ceruloplasmin, which can change blood levels and reflect kidney damage rather than a true primary copper problem. Several studies linked urinary ceruloplasmin loss or higher serum ceruloplasmin with diabetic kidney disease and albumin in the urine (14, 15, 16).
When To Look Deeper
A broader workup can help when the diabetes picture looks unusual. Useful tests may include serum copper, ceruloplasmin, ferritin, transferrin saturation, liver enzymes, fasting glucose, fasting insulin, HbA1c and urine protein. Genetic testing may be needed when low ceruloplasmin shows up with anemia, odd iron overload, eye findings or neurologic symptoms (5, 10).
A lean adult with diabetes and high ferritin deserves more attention than a quick label alone. The same goes for people with anemia that does not fit simple iron deficiency or a family history of unusual iron problems. Rare disease stays rare, though the clue pattern can be strong when several pieces line up.
What Research Shows
Strongest Link
The clearest diabetes risk appears in aceruloplasminemia. Reviews and case series show that low or absent ceruloplasmin can lead to iron buildup in the pancreas, liver, retina and brain. Diabetes can be one of the first signs long before the later nerve or movement problems appear (5, 7).
Ordinary diabetes is more complicated. Some studies report higher copper. Some report altered ceruloplasmin. Some show links with oxidative stress or kidney damage rather than simple deficiency. A broad claim that all diabetes comes from low copper would go far beyond the evidence currently available (3, 4, 13).
Plain Take
Low copper can affect insulin sensitivity in plausible ways because copper helps cells make energy and protect themselves from oxidative stress. The clearest clinical signal shows up in rare ceruloplasmin deficiency where iron handling breaks down and the pancreas can get injured. Common diabetes needs a more careful reading because lab patterns often shift with inflammation, kidney disease and disease stage rather than one simple mineral shortage.
For any health concerns or questions about a medical condition, get guidance from a physician or another appropriately trained clinician. Before changing your diet, supplements or health routine, talk with a licensed healthcare professional.
FAQs
Can low copper affect insulin sensitivity?
Yes. Copper helps enzymes that support cell energy and protection from oxidative stress. Poor copper handling can make tissues less able to respond well to insulin.
Is low ceruloplasmin the same as low copper?
No. Low ceruloplasmin can point to poor copper transport rather than a simple lack of copper intake. The full lab pattern gives a better answer.
Can ceruloplasmin deficiency cause diabetes?
Yes. Diabetes is a known feature of aceruloplasminemia and can show up before later brain symptoms in some people.
Why do some diabetes studies show high ceruloplasmin?
Ceruloplasmin can rise with inflammation. Kidney disease can change the numbers too. Lab results can move in different directions depending on what else is going on.
Which tests help assess low copper in diabetes?
Doctors may check ceruloplasmin, serum copper, ferritin, transferrin saturation, liver enzymes, glucose markers and urine protein. Some people may also need genetic testing.
Research
Lowe, J., Taveira da Silva, R., Hilário, E. and Teixeira, M. (2017) ‘Dissecting copper homeostasis in diabetes mellitus’, IUBMB Life, 69(4), pp. 255–262. Available at: https://pubmed.ncbi.nlm.nih.gov/28276155/
Liu, Z., Yu, H., Li, X. and Wang, Y. (2022) ‘Molecular Functions of Ceruloplasmin in Metabolic Disease Pathology’, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 15, pp. 695–711. Available at: https://pubmed.ncbi.nlm.nih.gov/35264864/
Qiu, Q., Zhang, F., Zhu, W., Wu, J. and Liang, M. (2017) ‘Copper in diabetes mellitus: A meta analysis and systematic review of plasma and serum studies’, Biological Trace Element Research, 177(1), pp. 53–63. Available at: https://pubmed.ncbi.nlm.nih.gov/27785738/
Eljazzar, S., Althomali, A., Alqurashi, K. and colleagues (2023) ‘The Role of Copper Intake in the Development and Management of Type 2 Diabetes: A Systematic Review’, Nutrients, 15(7), 1655. Available at: https://pubmed.ncbi.nlm.nih.gov/37049495/
Kono, S. (2013) ‘Aceruloplasminemia: an update’, International Review of Neurobiology, 110, pp. 125–151. Available at: https://pubmed.ncbi.nlm.nih.gov/24209437/
Gitlin, J.D. (1998) ‘Aceruloplasminemia’, Neuropathology, 18(4), pp. 406–410. Available at: https://pubmed.ncbi.nlm.nih.gov/9727700/
Vroegindeweij, L.H.P., Langendonk, J.G., Langeveld, M. and colleagues (2015) ‘Aceruloplasminemia presents as Type 1 diabetes in non obese adults: a detailed case series’, Diabetic Medicine, 32(8), pp. 993–1000. Available at: https://pubmed.ncbi.nlm.nih.gov/25661792/
Morita, H., Ikeda, S., Yamamoto, K. and colleagues (1995) ‘Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family’, Annals of Neurology, 37(5), pp. 646–656. Available at: https://pubmed.ncbi.nlm.nih.gov/7755360/
Okamoto, N., Wada, S., Oga, T. and colleagues (1996) ‘Hereditary ceruloplasmin deficiency with hemosiderosis’, Human Genetics, 97(6), pp. 755–758. Available at: https://pubmed.ncbi.nlm.nih.gov/8641692/
Xiao, Y., Liu, Y., Wang, X. and colleagues (2022) ‘Novel ceruloplasmin gene mutation causing aceruloplasminemia with diabetes in a Chinese woman: a case report’, Annals of Palliative Medicine, 11(7), pp. 2516–2522. Available at: https://pubmed.ncbi.nlm.nih.gov/34670377/
Sasaki, H., Takahashi, Y., Takei, K. and colleagues (1996) ‘Hereditary ceruloplasmin deficiency a new type of diabetes mellitus’, Internal Medicine, 35(8), pp. 596–597. Available at: https://pubmed.ncbi.nlm.nih.gov/8894730/
Kato, T., Kawarada, Y., Nakamura, T. and colleagues (1997) ‘Islet changes in hereditary ceruloplasmin deficiency’, Human Pathology, 28(4), pp. 499–502. Available at: https://pubmed.ncbi.nlm.nih.gov/9104952/
Gembillo, G., Siligato, R., Currò, M. and colleagues (2023) ‘Potential Role of Copper in Diabetes and Diabetic Kidney Disease’, Metabolites, 13(1), 17. Available at: https://pubmed.ncbi.nlm.nih.gov/36676942/
Narita, T., Sasaki, H., Hosoba, M. and colleagues (2006) ‘Increased urinary excretions of immunoglobulin G, ceruloplasmin, and transferrin predict development of microalbuminuria in patients with type 2 diabetes’, Diabetes Care, 29(1), pp. 142–144. Available at: https://pubmed.ncbi.nlm.nih.gov/16373913/
Lee, M.J., Jung, C.H., Kang, Y.M. and colleagues (2015) ‘Serum Ceruloplasmin Level as a Predictor for the Progression of Diabetic Nephropathy in Korean Men with Type 2 Diabetes Mellitus’, Diabetes & Metabolism Journal, 39(3), pp. 230–239. Available at: https://pubmed.ncbi.nlm.nih.gov/26124993/
Jung, C.H., Lee, M.J., Kang, Y.M. and colleagues (2011) ‘Elevated serum ceruloplasmin levels are associated with albuminuria in Korean men with type 2 diabetes mellitus’, Diabetes Research and Clinical Practice, 94(1), pp. e3–e7. Available at: https://pubmed.ncbi.nlm.nih.gov/21752484/
Ketata, I. and Ellouz, E. (2023) ‘New view of aceruloplasminemia: Systematic review and meta analysis tracking dots from onset to disease development and iron related features’, Rare, 1, 100010. Available at: https://doi.org/10.1016/j.rare.2023.100010
Sanjeevi, N., Nandhini, A.T.A., Suresh, S. and colleagues (2018) ‘Trace element status in type 2 diabetes: A meta analysis’, Journal of Clinical and Diagnostic Research, 12(5), pp. OE01–OE08. Available at: https://pubmed.ncbi.nlm.nih.gov/29911075/
Narita, T., Hosoba, M., Kakei, M. and colleagues (2004) ‘Parallel increase in urinary excretion rates of immunoglobulin G, ceruloplasmin, transferrin, and orosomucoid in normoalbuminuric type 2 diabetic patients’, Diabetes Care, 27(5), pp. 1176–1181. Available at: https://pubmed.ncbi.nlm.nih.gov/15111541/
Yamazaki, M., Takei, K., Fujikawa, T. and colleagues (1995) ‘Urinary excretion rate of ceruloplasmin in non insulin dependent diabetic patients with different stages of nephropathy’, European Journal of Endocrinology, 132(6), pp. 681–687. Available at: https://pubmed.ncbi.nlm.nih.gov/7788006/
Cui, Z., Wang, T., Wang, J. and colleagues (2022) ‘The Association Between Plasma Copper Concentration and Prevalence of Diabetes in Chinese Adults With Hypertension’, Frontiers in Public Health, 10, 888219. Available at: https://pubmed.ncbi.nlm.nih.gov/35747779/
Sarkar, A., Dash, S., Barik, B.K. and colleagues (2010) ‘Copper and Ceruloplasmin Levels in Relation to Total Thiols and GST in Type 2 Diabetes Mellitus Patients’, Indian Journal of Clinical Biochemistry, 25(1), pp. 74–76. Available at: https://pubmed.ncbi.nlm.nih.gov/23105888/
Cunningham, J., Leffell, M., Mearkle, P. and Harmatz, P. (1995) ‘Elevated plasma ceruloplasmin in insulin dependent diabetes mellitus: evidence for increased oxidative stress as a variable complication’, Metabolism, 44(8), pp. 996–999. Available at: https://pubmed.ncbi.nlm.nih.gov/7637657/
Nowak, M., Wielkoszyński, T., Marek, B. and colleagues (2010) ‘Antioxidant potential, paraoxonase 1, ceruloplasmin activity and C reactive protein concentration in diabetic retinopathy’, Clinical and Experimental Medicine, 10(3), pp. 185–192. Available at: https://pubmed.ncbi.nlm.nih.gov/20012460/
Satyanarayana, G., Balakrishnan, S., Srikanth, S. and colleagues (2021) ‘Evaluation of Serum Ceruloplasmin Levels as a Biomarker for Oxidative Stress in Patients With Diabetic Retinopathy’, Cureus, 13(2), e13070. Available at: https://pubmed.ncbi.nlm.nih.gov/33680612/
